Opuviz aflibercept biosimilar debuts in Europe for retinal disease treatmentByLucia GambuzzaJune 2nd 2026Samsung Bioepis launched Opuviz, an aflibercept biosimilar, in Europe for wet AMD, DME, retinal vein occlusion, and myopic CNV.